The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Unmet needs in MPN treatment
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses unmet needs in the treatment of myeloproliferative neoplasms (MPNs). Dr Mesa first explains that achieving deep and complete remissions is one of the major unmet needs in this field. Following this, Dr Mesa mentions some agents which have improved treatment options over the years, including ruxolitinib and other JAK inhibitors, and concludes by explaining the need to continue to improve disease burden and survival in patients. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
